Specialty Chemicals company Epigral announced Q3FY26 results Plant utilization stood at 78% similar to previous quarter. The company posted a revenue of Rs 603 crore for Q3FY26 as against Rs 649 crore recorded in Q3YF25. EBITDA margin stood at 17% vs 23% in Q2FY26 on account of drop in realizations and increase in cost of raw materials. PAT stood at Rs 39 crore compared to Rs 104 crore in Q3FY25. Maulik Patel, Chairman & Managing Director, Epigral said: “This quarter delivered marginal sequential topline growth. While demand softened before mid-November due to extended monsoon conditions, the market has strengthened notably since then, and we anticipate sustained positive momentum ahead. Margins in Q3FY26 reflected temporary pressures from softer realizations on select products, elevated raw material costs, and inventory dynamics. With the improving market scenario, we anticipate positive outcomes starting Q4FY26. Our capacity expansion projects for CPVC, Epichlorohydrin, and Wind Solar Hybrid Power Plant are progressing smoothly on schedule, set for timely commissioning. These initiatives will drive growth from FY27 onwards. We're also advancing new projects and look forward to sharing updates soon. We remain committed to our journey of scalable, profitable growth optimizing capital allocation, enhancing integration, and delivering lasting value for all stakeholders.” Result PDF